The new Institute of Cancer Research spinout company Sentinal4D has been announced to the public
The Institute of Cancer Research shared on LinkedIn:
“Great news to round out 2024 here at the ICR!
We’re delighted to share that the new ICR spinout company Sentinal4D has been announced to the public.
Sentinal4D aims to accelerate drug discovery and development to target drugs to patients, powered via patented artificial intelligence-driven methods for personalised therapeutics.
The company is built on years of data and expertise developed in the lab of ICR’s Professor Chris Bakal, a leading expert in cell shape in cancer, and includes former ICR PhD Student Matt De Vries. It is led by Dr. Georgia Mitsi.
Professor Bakal said: ‘Sentinal4D brings together several strands of expertise we’ve been building in the lab for a number of years – including a deepening understanding of the role of cellular shape-shifting in cancer, innovative new methods of drug discovery, and AI-driven analysis of data including image data.’
Sentinal4D is the second spinout company to be announced by the ICR this year – as we continue to support our entrepreneurial scientists.
Dr. Jon Wilkinson, Director of Business and Innovation at the ICR said:
‘Sentinal4D is the latest of several new spinout companies to emerge from our work at the ICR, as we continue to encourage scientists to found companies as part of the mix of what they do.’
Read more here.”
More posts featuring The Institute of Cancer Research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023